# Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

> **NCT03057743** · — · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 4 (actual)

## Conditions studied

- METASTATIC BREAST CANCER

## Interventions

- **DEVICE:** Positron emission tomography (PET/CT) imaging
- **DEVICE:** radiotracer [18F]ISO-1

## Key facts

- **NCT ID:** NCT03057743
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-05
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Difficulty enrolling subjects
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057743, "Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03057743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*